Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Common Stock Repurchased
Cash spent buying back the company's own shares.
Atrium Therapeutics, Inc.NASDAQ: RNA
Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026
Common stock repurchased of $0 in Q1 FY2026
Q1 FY2026 common stock repurchased was $0.
Context
- Common stock repurchased amounted to 0.0% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Repurchased history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Common Stock Repurchased | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
Common Stock Repurchased vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Common Stock Repurchased figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.